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There has been much uncertainty as to whether metastasis requires mutation at the time of spread. Here, we use clinical data to
calculate the probability of the spread of melanoma and breast cancer cells. These calculations reveal that the probability of the
spread of cancer cells is relatively high for small tumours (B1 event of spread for every 500 cells for melanomas of 0.1mm) and
declines as tumours increase in size (B1 event of spread for every 10
8 cells for melanomas of 12mm). The probability of spread of
breast cancer cells from the lymph nodes to the periphery is B1 event of spread for every 10
8 cells in the nodal masses, which have a
mean diameter of 5mm, while the probability of spread of cancer cells from the breast to the periphery when the primary masses are
5mm is also B1 event of spread for every 10
8 cells. Thus, the occurrence of an event of spread from the breast to the lymph nodes
appears not to increase the propensity of the progeny of those cells to spread from the lymph nodes to the periphery. These values
indicate that the spread of human breast cancer and melanoma cells is unlikely to occur by a mechanism requiring mutation at the
time of spread.
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There has been much uncertainty as to whether metastasis requires
mutation at the time of spread (Cifone and Fidler, 1981; Fidler,
1983; Sobel, 1990; Welch et al, 2000; Yokota, 2000; Bernards and
Weinberg, 2002; Couzin, 2003; Bernards, 2003; Van’t Veer and
Weigelt, 2003; Yang et al, 2004). Mutations have a number of
characteristic features, in terms of the rates of their occurrence and
other qualities, which are diagnostic: mutations are rare, a
phenotype conferred on a cell by mutation is inherited by the
progeny of the cell, and the rates of the appearance of phenotypes
caused by mutations either remains constant over time for those
phenotypes requiring only a single mutation, or increase in
frequency for those phenotypes requiring the accumulation of
multiple mutations. We have recently shown that from clinical
data it is possible to measure the rates of metastatic spread,
expressed in terms of the probability of spread per cell
(Michaelson, 1999; Michaelson et al, 2002, 2003). Here we use
this methology to measure the probability of spread per cell for
human breast cancer and melanoma. The values of these
probabilities are inconsistent with metastasis occurring by a
process of mutation.
METHODS
Data
Data on the relationship between tumour size and breast cancer
survival is from the USC/Van Nuys population (Silverstein, 2000;
Michaelson et al, 2002, 2003), from Tabar et al (2000) and Tubiana
and colleagues (Koscielny et al, 1984; Tubiana and Koscielny, 1990,
1991). For details and the general equivalence of these survival
values (based on the 15-year Kaplan–Meier survival rate, based
upon Karrison et al (1999) finding that it is not until this point in
time that the survival rate become clear), see Michaelson et al
(2002, 2003). Data on the relationship between tumour thickness
and melanoma survival are 10-year Kaplan–Meier disease survival
values from Balch et al, 2001).
Tumour diameters (breast cancer) and thickness (melanoma)
were taken at pathological analysis. Since we shall be interested in
tumour size in terms of the number of cells that they contain, N,
we can generate rough estimates of the value of N that are quite
satisfactory for our purposes here by converting values of tumour
diameter or thickness, D, into values of cell number, N, assuming
spherical geometry and a density of s (here we shall use 10
8 cells/
cm
3 as a biologically plausible estimate of, s, as outlined in Boon
et al, 1982; Pesce and Colacino, 1986; Van der Linden et al, 1986;
and Michaelson et al, 2002). While this estimate of the value of s is
biologically reasonable, for the purposes of the calculations made
here, it need not be precise, as any error in the estimation of s by
an order of magnitude or more will not change the general lessons
Revised 15 June 2005; accepted 7 September 2005; published online
8 November 2005
*Correspondence: Dr JS Michaelson, Division of Surgical Oncology, Cox
Building Room 626, Massachusetts General Hospital, 100 Blossom Street,
Boston, MA 02114, USA;
E-mail: michaelj@helix.mgh.harvard.edu
British Journal of Cancer (2005) 93, 1244–1249
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdrawn here on the nature of cancer spread, although it will affect
the precise values of the probability of spread.
Node-positive patients are defined as those patients with one or
more lymph nodes found to have cancer upon pathological
analysis. The range of nodes examined among women in the USC/
Van Nuys populations varied from 1 to 47; however, only 10% of
women had fewer than 10 nodes examined, while only 2% of
women had fewer than five nodes examined. The mean and median
number of nodes examined was 16.8 and 17, with a s.d. of 7.2.
Information on the size of the cancer metastases in the lymph
nodes was collected from microscope slides from 16 node-positive
patients, chosen at random, among MGH patients with invasive
breast cancer diagnosed in 1993, among which there were 49
positive lymph nodes. Microscopic imagines of each node were
Table 1 Data and calculations of the probability of the spread of cancer cells
Cancer Population
Size
range
Nominal
tumour size
(mm)
Cell number
(N)
Manifestation of
metasatasis
Fraction of patients
with a manifestation of
metastasis (L)( % )
Probability of
spread
(p¼ ln(1 L)/N)
Breast cancer Tabar et al 10–14 12 9.05E+07 Cancer death 13 1/6.5 10
8
Breast cancer Tabar et al 15–19 17 2.57E+08 Cancer death 20 1/1.2 10
9
Breast cancer Tabar et al 20–29 25 8.18E+08 Cancer death 45 1/1.4 10
9
Breast cancer Tabar et al 30–49 39 3.11E+09 Cancer death 56 1/3.9 10
9
Breast cancer Tubiana et al 10–25 17 2.57E+08 Cancer death 27 1/8.2 10
8
Breast cancer Tubiana et al 26–35 30 1.41E+09 Cancer death 42 1/2.6 10
9
Breast cancer Tubiana et al 36–45 40 3.35E+09 Cancer death 55 1/4.1 10
9
Breast cancer Tubiana et al 46–55 50 6.54E+09 Cancer death 66 1/6.1 10
9
Breast cancer Tubiana et al 56–65 60 1.13E+10 Cancer death 78 1/7.4 10
9
Breast cancer Tubiana et al 66–75 70 1.80E+10 Cancer death 83 1/1.0 10
10
Breast cancer Tubiana et al 76–85 80 2.68E+10 Cancer death 81 1/1.6 10
10
Breast cancer Tubiana et al 86–95 90 3.82E+10 Cancer death 92 1/1.5 10
10
Breast cancer Van nuys 10–14 12 9.05E+07 Cancer death 14 1/6.0 10
8
Breast cancer Van nuys 15–19 17 2.57E+08 Cancer death 28 1/7.8 10
8
Breast cancer Van nuys 20–29 25 8.18E+08 Cancer death 33 1/2.0 10
9
Breast cancer Van nuys 30–49 39 3.11E+09 Cancer death 46 1/4.0 10
9
Breast cancer Van nuys 15–19 17 2.57E+08 Cancer in nodes 32 1/6.7 10
8
Breast cancer Van nuys 20–24 22 5.58E+08 Cancer in nodes 39 1/1.1 10
9
Breast cancer Van nuys 25–29 27 1.03E+09 Cancer in nodes 39 1/2.1 10
9
Breast cancer Van nuys 30–34 32 1.72E+09 Cancer in nodes 50 1/2.5 10
9
Breast cancer Van nuys 35–39 37 2.65E+09 Cancer in nodes 54 1/3.4 10
9
Breast cancer Van nuys 40–44 42 3.88E+09 Cancer in nodes 63 1/3.9 10
9
Breast cancer Van nuys 45–50 47 5.44E+09 Cancer in nodes 54 1/7.1 10
9
Breast cancer Van nuys 50–54 52 7.36E+09 Cancer in nodes 59 1/8.3 10
9
Melanoma Balch et al — 0.10 5.3E+01 Cancer death 11 1/480
Melanoma Balch et al — 0.23 6.8E+02 Cancer death 9 1/7100
Melanoma Balch et al — 0.37 2.6E+03 Cancer death 10 1/2.4 10
4
Melanoma Balch et al — 0.44 4.3E+03 Cancer death 14 1/2.9 10
4
Melanoma Balch et al — 0.50 6.7E+03 Cancer death 18 1/3.4 10
4
Melanoma Balch et al — 0.60 1.2E+04 Cancer death 22 1/4.5 10
4
Melanoma Balch et al — 0.70 1.8E+04 Cancer death 18 1/9.1 10
4
Melanoma Balch et al — 0.84 3.1E+04 Cancer death 20 1/1.4 10
5
Melanoma Balch et al — 0.91 3.9E+04 Cancer death 23 1/1.5 10
5
Melanoma Balch et al — 0.97 4.8E+04 Cancer death 21 1/2.0 10
5
Melanoma Balch et al — 1.11 7.1E+04 Cancer death 20 1/3.1 10
5
Melanoma Balch et al — 1.17 8.5E+04 Cancer death 27 1/2.7 10
5
Melanoma Balch et al — 1.31 1.2E+05 Cancer death 30 1/3.3 10
5
Melanoma Balch et al — 1.38 1.4E+05 Cancer death 25 1/4.8 10
5
Melanoma Balch et al — 1.51 1.8E+05 Cancer death 30 1/5.0 10
5
Melanoma Balch et al — 1.58 2.1E+05 Cancer death 25 1/7.1 10
5
Melanoma Balch et al — 1.71 2.6E+05 Cancer death 30 1/7.1 10
5
Melanoma Balch et al — 1.85 3.3E+05 Cancer death 32 1/8.3 10
5
Melanoma Balch et al — 1.88 3.5E+05 Cancer death 38 1/7.1 10
5
Melanoma Balch et al — 1.98 4.1E+05 Cancer death 44 1/7.1 10
5
Melanoma Balch et al — 2.11 4.9E+05 Cancer death 40 1/1.0 10
6
Melanoma Balch et al — 2.25 6.0E+05 Cancer death 45 1/1.0 10
6
Melanoma Balch et al — 2.52 8.3E+05 Cancer death 36 1/1.9 10
6
Melanoma Balch et al — 2.72 1.1E+06 Cancer death 45 1/1.8 10
6
Melanoma Balch et al — 3.02 1.4E+06 Cancer death 47 1/2.3 10
6
Melanoma Balch et al — 3.39 2.0E+06 Cancer death 50 1/2.9 10
6
Melanoma Balch et al — 3.72 2.7E+06 Cancer death 54 1/3.4 10
6
Melanoma Balch et al — 4.26 4.1E+06 Cancer death 54 1/5.3 10
6
Melanoma Balch et al — 4.73 5.5E+06 Cancer death 55 1/7.1 10
6
Melanoma Balch et al — 5.27 7.7E+06 Cancer death 59 1/8.3 10
6
Melanoma Balch et al — 5.77 1.0E+07 Cancer death 57 1/1.2 10
7
Melanoma Balch et al — 6.74 1.6E+07 Cancer death 63 1/1.6 10
7
Melanoma Balch et al — 7.75 2.4E+07 Cancer death 65 1/2.3 10
7
Melanoma Balch et al — 12.32 9.8E+07 Cancer death 76 1/6.7 10
7
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scaptured with a Nikon Eclipse E400 microscope equipped with an
Insight digital camera (Diagnostic Instruments Inc., Sterling
Heights, MI, USA), used to capture high-resolution noninter-
polated image with a  10 objective. The image measurements
were calibrated by comparison to an image of the 1mm grating on
a haemocytometer. The longest dimension of the metastasis was
measured from prints made of the images. All slides were reviewed
by a qualified breast pathologist (DS). In some nodal metastases,
noncancerous cells were apparent within the mass of cancer, and
the sizes of these cancerous and noncancerous areas were
measured. Thus, the values labelled ‘Diameter (corrected)’
(Table 3) were corrected with respect to the cancerous component
of each metastasis, and thus were representative of the size that a
mass of cancer would have had, had it shown the same number of
cells but no noncancerous component.
Mathematical methods
Following the line of thinking outlined previously (Michaelson
et al, 2002), let us define p as the probability of a single successful
event of metastatic spread prior to surgery per unit of tumour
volume, s. When the value of s is chosen so as to be to be
equivalent to the volume of a cell, then p, from a practical
standpoint, is also the probability of spread per cell, N. Note that
by defining p on a per volume or per-cell basis, we are not
assuming that every cell in the tumour has the potential to spread.
For example, if we find that in a specific context, p¼1-in-ten-
billion, then we shall not mean that every cell in the tumour mass
will have such a chance of spread. Rather, this simply means that
for every ten billion cells in a tumour, there will be about one event
of metastatic spread. Note also that we have defined p as the
probability of an event of spread, which can be either the spread of
a single cell or a cluster of cells. Additionally, since we are defining
p in terms of successful events of spread, that is events of spread
that go on to give rise to evident cancer in the local nodes, or to
give rise to distant metastatic disease, we are not concerned with
those events of spread that do not result in such manifestations of
metastasis. Let us define L as the fraction of patients displaying the
occurrence of such an event of spread. If we are interested in
examining the probability of the lethal spread of cells to the
periphery, resulting in metastatic disease, then L will be the
fraction of patients dying of the cancers; while if we are interested
in measuring the nonlethal spread of cancer cells to the lymph
nodes, then L will be the fraction of patients with cancer found in
the nodes upon pathological analysis. It follows that (1-L) will be
the fraction of the fraction of patients not displaying the
occurrence of spread Similarly, as p is the per-cell probability of
an event of spread, the probability that there will not be an event of
spread will be (1-p), and the overall probability that a tumour of N
cells has not given rise to one or more such metastases will be
(1-p)
N. It has long been appreciated that for small values of p,
(1-p)
N can very well be approximated by e
-Np, and thus:
1   L ¼ e Np ð1Þ
Rearranging provides a way to estimate the probability of spread
(p) per cell (N):
p ¼ lnð1   LÞ=N ð2Þ
RESULTS
From clinical data, we are able to observe the consequences of
several examples of the spread of cancer cells, and their
probabilities: the lethal spread of breast cancer and melanoma
cells from the primary site to the periphery (pBC-overall and
pMEL-overall); and the nonlethal spread of breast cancer cells from
the primary site to the local nodes (pBC-to-nodes), and the lethal
spread of breast cancer cells from the lymph nodes to the periphery
(pBC-from-nodes) (Tables 1 and 2). To see the general approach for
estimating the values of these probabilities, consider the simple
example of a group of patients with tumours containing a billion
cells (N¼10
9 cells, B3cm), of whom 10% have died of metastatic
disease (L¼0.1). If we assume, for explanatory purposes, that each
death was the result of the spread of a single cell from the primary
site to the periphery (an assumption not made in the math outlined
in equations (1) and (2) above) then it follows that the probability
(p) of lethal spread is approximately 1 event of spread for every ten
billion cells in the primary mass (pEL/N¼0.1/10
9). Similarly, if
about 1% patients with a different type of tumour, but of the same
size (N¼10
9 cells), have died of metastatic disease (L¼0.01), then
it follows that the probability of lethal spread (p) is about 1 event of
spread for every hundred billion cells (pEL/N¼0.01/10
9).
Equation (2) provides the technique for accurately quantifying
the probabilities of these types of cancer spread. In three instances
(pBC-overall, pMEL-overall and pBC-to-nodes, Tables 1 and 2), data are
available on spread from tumours of various sizes, revealing that
the probability values do not remain constant as tumours grow,
but declines as tumours increase in size (Figures 1 and 2). For
example, the probability of lethal spread of melanoma cells from
the primary site in the skin to the periphery (pMEL-overall)i sB1
event of spread for every 500 cells for melanomas of 0.1mm, but
Table 2 The values of the probabilities of various events of cancer spread
Metastatic event
Probability of spread
per cell p¼-ln(1-L)/N
Source of information
for the value of L
Value of p the probability
of spread per cell for
tumour masses of B5mm
Nature of relationship
between the value of p
and tumour size
Lethal spread of breast cancer from
the primary site in the breast to
periphery, pathway unknown
pBC-overall LBC-overall¼the fraction of
breast cancer deaths
among all patients
8.27 10
 9 p¼aN
b
aBC-overallE0.000056
bBC-overallE-0.56203
Lethal spread of melanoma from
the primary site in the skin to
periphery, pathway unknown
pMEL-overall LMEL-overall¼the fraction of
melanoma deaths among all
patients
1.23 10
 7 p¼aN
b
aMEL-overallE0.027
bMEL-overallE-0.7836
Nonlethal spread of breast cancer
from the primary site in the breast
to the lymph nodes
pBC-to-nodes LBC-to-nodes¼the fraction of
node positive patients
among all patients
1.75 10
 8 p¼aN
b
aBC-to-nodesE0.000092
bBC-to-nodesE-0.69251
Lethal spread of breast cancer from
the lymph nodes to the periphery
pBC-from-nodes LBC-from-nodes¼6.08%, the
lethal contribution per
positive lymph node
7.96 10
 9a Undefined
aThe size of nodal metastases was found to have a mean value of 5.3mm (Table 3). The value shown here for pBC-overall is for a mass of 5mm; for 5.3mm,
pBC-overall¼7.49 10
 09.
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s100,000-fold lower (B1 event of spread for every 10
8 cells) for
12mm tumours (Figure 1). As we have reported previously
(Michaelson et al, 2002), a similar decline in the probability of
spread per cell is also seen as tumours become larger for the
overall probability of lethal spread of breast cancer cells from the
primary site in the breast to the periphery (pBC-overall, Figure 1). As
can also be seen in Figure 1, a similar decline in the probability
of spread per cell occurs for the nonlethal spread of breast
cancer cells from the primary site in the breast to the lymph nodes
(pBC-to-nodes, Figure 2) (Tables 1 and 2). Furthermore, in each of the
three contexts this decline occurs in a highly predictable fashion
with N, such that it is well fit (Figures 1 and 2) to a power function
of the form:
p ¼ aNb ð3Þ
Values for a and b for each of these three types of metastatic spread
are shown in Table 2. b has a negative value of approximately  0.5
to  0.8, reflecting the fact that the value of p declines as tumours
increase in size. a can be thought of as the probability of spread for
the very first cell in the tumour, because p¼a when N¼1.N o t e
that the parameter a is approximately 500-fold higher for
melanoma than for breast cancer, reflecting the long-appreciated
greater propensity of melanoma to give rise to metastases.
There are a number of possible explanations for why the
probability of spread per cell, p, declines as tumours become
larger. It could be that only a subpopulation of tumour cells are
capable of metastasising, and that the relative abundance of these
cells decline as tumours grow. Another possibility is that the
decline in the per-cell probability of spread is the result of the
simple geometrical constraints posed to the escape of cells from
the primary mass (Padera et al, 2002), which become more
formidable as tumours increase in size. As shown in the
Supplementary material, such possibilities are mathematically
possible, and are testable in experimental systems (Figure 3).
The spread of cancer cells can occur in single steps, such as the
spread of a cell directly from the primary site to the periphery, or
in multiple steps, such as the initial spread of a cell from the
primary site to a local lymph nodes followed by the subsequent
spread of one of the progeny of that cell away from the node to the
periphery. By measuring the breast cancer death rate among
subpopulations of patients sorted by both the size of the primary
mass and the number of such positive lymph nodes, we have
recently found that the presence of each positive node is associated
with an extra 6.08% chance of death (Michaelson et al, 2003). It is
possible to use this information with equation (2) to measure the
probability of the spread of breast cancer cells from the nodes to
the periphery (pBC-from-nodes). To carry out this calculation, we set
1
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Figure 1 Calculations of the probability of lethal spread of breast cancer
and melanoma cells, as a function of tumour size, and the close fit of the
data to equation (2). (R
2¼0.98 for breast cancer, (R
2¼0.9 for melanoma).
Shown here are the overall values for the probability of lethal spread of
cancer cells from the primary site to the periphery for breast cancer (pBC-
overall) and melanoma (pMEL-overall) using tumour size/survival data for all
patients (Table 1). Note the close fit to the power function, equation (3).
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Figure 2 Calculations of the probability of lethal spread of breast cancer from the primary site to the periphery (pBC-overall) by equation (2) and
using tumour size/survival data for all patients (Table 1), and the probability of nonlethal spread of breast cancer from the primary site to the lymph nodes
(pBC-to-nodes) by equation (2) and using tumour size/nodal status data (Table 1). Note that in both cases the relationship between the probability of spread
and tumour size is well fit by a power function, equation (3).
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sthe value of L¼0.0608, and to determine the value of N,w e
collected data on the sizes of metastases in lymph nodes, revealing
a mean size of 5.3mm, which is equivalent to N¼7.84 10
6
cells (Table 3). It follows with equation (2) that the probability
of the spread of cancer cells from lymph nodes pBC-from-nodes¼
7.96 10
 09E1 event of spread for every 10
8 cells. This value is
remarkably close to the value for the probability of the lethal
spread of breast cancer cells from the primary mass in the breast
when the primary mass is also 5.3mm (pBC-overall¼7.49 10
 09),
as calculated by extrapolation of equation (3). This reveals that the
occurrence of an event of spread of cancer cells from the primary
site in the breast to the local lymph nodes does not appreciably
change the tendency of the progeny of those cancer cells to make
yet a second event of spread from the lymph nodes to the
periphery.
DISCUSSION
It has often been wondered whether mutation at the time of spread
is a requirement for metastasis (Cifone and Fidler, 1981; Fidler,
1983; Sobel, 1990; Welch et al, 2000; Yokota, 2000; Bernards and
Weinberg, 2002; Couzin, 2003; Bernards, 2003), but the values of
the probabilities of metastatic spread of breast cancer and
melanoma cells revealed by equation (2) are difficult to reconcile
with such genetic changes due to several reasons: First, the value of
the probability of spread for the smallest melanomas (0.1mm), at
B1 event of spread for every 500 cells, is many orders of
magnitude greater than that expected for a genetic change. Second,
the occurrence of one event of spread (the spread of breast cancer
cells from the breast to the local lymph nodes) does not appear to
increase the chance of a second event of spread (the spread of
breast cancer cells from the local lymph nodes to the periphery). In
other words, the occurrence of the initial event of spread does not
lead to a cell-heritable change in the tendency of the progeny of
that cell to spread. Third, the data shown here reveal that the
probability of metastatic spread per cell declines as tumours
increase in size. While this decline is consistent with a number of
explanations that are mechanical, (using this term in the sense in
which it is used in physics: ‘pertaining to the relations of force and
matter’), such as the effect of tumour geometry on the ease of the
escape of cells from the primary mass (see Supplementary
material), it is not what would be expected for genetic events.
Indeed, the probability of genetic events over time should be
expected either to remain constant (if only a single genetic event is
required) or to increase with time (if the accumulation of multiple
genetic events is required). Taken together, these findings would
appear to be in agreement with the viewpoint put forward by
Bernards and Weinberg ‘that the tendency to metastasise is largely
determined by the identities of mutant alleles that are acquired
relatively early during multistep tumorigenesis’, and that ‘genes
and genetic changes specifically and exclusively involved in
orchestrating the process of metastasis do not exist’ (Bernards
and Weinberg, 2002).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
Time = t1
Tumour
Lymph duct
Lymph
node
Lymph
node
Lymph
node
Lymph duct Lymph duct
Tumour Tumour
Time = t2 Time = t3
Figure 3 Schematic of Geometrical Model #1. Shown is a highly
idealised image of a tumour mass and a lymph duct leading to a local lymph
node.
Table 3 Sizes of the invasive breast cancer metastases seen in the lymph
nodes
Node
number
Patient
number
Diameter
(mm)
Fraction of the
metastatic area
containing cancer (%)
Diameter
(corrected)
49 16 0.3 100 0.3
32 9 1 100 1
20 3 1 100 1
31 8 1.1 100 1.1
43 14 1.4 100 1.4
41 14 1.9 65 1.5
17 2 2 100 2
21 4 2 95 2
39 12 2.1 100 2.1
13 2 2.5 93 2.4
29 7 2.7 95 2.6
15 2 3 95 2.9
30 7 3 100 3
36 12 3 95 3
2 1 3.2 10 3.2
22 5 3.4 95 3.3
5 1 3.4 93 3.3
34 10 3.7 95 3.7
37 12 3.9 100 3.9
4 1 3.9 86 3.6
47 15 4.3 95 4.2
35 11 4.5 95 4.4
40 13 5.4 95 5.2
6 1 5.4 86 5
16 2 5.4 100 5.4
23 5 5.5 76 4.8
33 10 5.5 78 4.9
24 5 6 80 5.4
48 15 6 90 5.7
42 14 6.4 10 6.4
45 14 7.1 60 5.5
10 2 7.1 100 7.1
11 2 7.1 100 7.1
12 2 7.7 95 7.5
18 2 8 43 5.2
19 2 9 72 7.6
46 14 9 90 8.5
28 6 9 80 8
1 1 9.8 84 9
44 14 10 49 7
9 2 10 65 8.1
3 1 10 86 9.3
14 2 10 95 9.7
7 1 10.7 55 7.9
26 6 11 35 6.5
8 2 11 95 10.7
25 6 12.5 45 8.4
27 6 14.5 85 13.4
38 12 15 100 15
Average 5.95 86 5.31
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